Sanofi earns CHMP backing to expand Sarclisa's use for newly diagnosed multiple myeloma patients eligible for transplant.

JNJ wins CHMP backing for Darzalex and Imbruvica in new blood cancer uses, paving the way for first-in-class approvals.

Karolinska University Hospital has, for the first time in Sweden, begun preparations to treat a patient with multiple myeloma ...

Twelve years ago, while coaching in the Southeastern Conference at the University of Kentucky, his life took an unexpected ...

Karolinska University Hospital has, for the first time in Sweden, begun preparations to treat a patient with multiple myeloma ...

Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma <li /> Recommendation base ...

Discover why Genmab A/S stands out as a high-margin biotech with strong partnerships, robust growth prospects, and ...

2 Today, treatment for multiple myeloma often involves an intensive combination of chemotherapy, steroids, immunomodulatory drugs, and bone marrow transplants to slow down this multiplication and ...

Innovent Biologics is pivoting to R&D and oncology growth in China, but high valuation and risks temper upside. Read why ...

Global Antibody Drug Conjugate Market is valued at approximately USD 5.60 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 16.12% over the forecast period 2024-2030.

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...

Dr. Joshua Sabari and Dr. Nausheen Ahmed sat down to discuss topline takeaways in the realm of hematologic malignancies following the 2025 ASCO Meeting.